Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Ovid Technologies (Wolters Kluwer Health)  (2)
  • 1
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 2021
    In:  Nuclear Medicine Communications Vol. 42, No. 10 ( 2021-10), p. 1130-1134
    In: Nuclear Medicine Communications, Ovid Technologies (Wolters Kluwer Health), Vol. 42, No. 10 ( 2021-10), p. 1130-1134
    Abstract: Studies demonstrating limited accuracy of ‘positive’ and ‘negative’ lymph nodes on fluorodeoxyglucose (FDG) PET-CT in staging for lung cancer have led to guidelines stating mediastinal nodes enlarged on computed tomography, irrespective of FDG uptake, require endobronchial ultrasound (EBUS)-transbronchial needle aspiration (TBNA). However FDG uptake occurs on a continuous spectrum and the use of standardised uptake value (SUV) max ratios, rather than a binary classification, may have improved diagnostic accuracy. Methods This was a retrospective analysis of patients with lung cancer who had PET-CT and EBUS-TBNA in 2015–2018. Results from EBUS and the SUV max ratio of sampled lymph nodes to mediastinal blood pool (SUV max LN/MBP) were analysed. Results From 99 patients 102 malignant and 54 benign nodes were identified. The SUV max range was 2.5–52 for malignant and 1.6–5.4 for benign nodes. The SUV max LN/MBP was 1.3–23 for malignant and 0.7–2.3 for benign nodes. All nodes with SUV max LN/MBP 〈 1.3 were benign with 100% negative predictive value (NPV). All nodes with SUV max LN/MBP 〉 2.3 were malignant with 100% positive predictive value (PPV). Conclusion In this relatively small sample, SUV max LN/MBP 〈 1.3 had a NPV of 100% for excluding malignant nodes and SUV max LN/MBP 〉 2.3 had a PPV of 100% for diagnosing malignant nodes. Using SUV max ratios could obviate the need for staging EBUS in selected patients with resultant time and cost savings. Selecting different SUV max ratios, chosen to provide high accuracies for the parameter of interest to change management, is a potentially powerful diagnostic tool that is overlooked when FDG uptake is only classified as ‘positive’ or ‘negative’.
    Type of Medium: Online Resource
    ISSN: 0143-3636
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2021
    detail.hit.zdb_id: 2028880-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Circulation: Genomic and Precision Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 14, No. 1 ( 2021-02)
    Abstract: Approximately 25% of patients with pulmonary arterial hypertension (PAH) have been found to harbor rare mutations in disease-causing genes. To identify missing heritability in PAH, we integrated deep phenotyping with whole-genome sequencing data using Bayesian statistics. Methods: We analyzed 13 037 participants enrolled in the NBR study (NIHR BioResource—Rare Diseases), of which 1148 were recruited to the PAH domain. To test for genetic associations between genes and selected phenotypes of pulmonary hypertension, we used the Bayesian rare variant association method BeviMed. Results: Heterozygous, high impact, likely loss-of-function variants in the kinase insert domain receptor ( KDR ) gene were strongly associated with significantly reduced transfer coefficient for carbon monoxide (posterior probability=0.989) and older age at diagnosis (posterior probability=0.912). We also provide evidence for familial segregation of a rare nonsense KDR variant with these phenotypes. On computed tomographic imaging of the lungs, a range of parenchymal abnormalities were observed in the 5 patients harboring these predicted deleterious variants in KDR . Four additional PAH cases with rare likely loss-of-function variants in KDR were independently identified in the US PAH Biobank cohort with similar phenotypic characteristics. Conclusions: The Bayesian inference approach allowed us to independently validate KDR , which encodes for the VEGFR2 (vascular endothelial growth factor receptor 2), as a novel PAH candidate gene. Furthermore, this approach specifically associated high impact likely loss-of-function variants in the genetically constrained gene with distinct phenotypes. These findings provide evidence for KDR being a clinically actionable PAH gene and further support the central role of the vascular endothelium in the pathobiology of PAH.
    Type of Medium: Online Resource
    ISSN: 2574-8300
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2021
    detail.hit.zdb_id: 2927603-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages